NCT04498676 (HRIPT) is a NA clinical trial of CB-0002B in Erythema, sponsored by CAGE Bio Inc..

Who is sponsoring NCT04498676?

NCT04498676 is sponsored by CAGE Bio Inc..

What drugs are being tested in NCT04498676?

Interventions in NCT04498676: CB-0002B.

What condition does NCT04498676 study?

NCT04498676 studies Erythema, Sensitisation.

Is NCT04498676 still recruiting?

NCT04498676 is currently completed. Last updated 4 August 2020.

Last reviewed 2020-08-04 · How we verify

NCT04498676: HRIPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

50 Human Subject Repeat Insult Patch Test

Completed NA Last updated 4 August 2020

What this trial tests

NA trial testing CB-0002B in Erythema in 50 participants. Completed in 2 March 2017.

Timeline

18 January 2017

Primary endpoint
8 February 2017

2 March 2017

Quick facts

Lead sponsor	CAGE Bio Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	50
Start date	18 January 2017
Primary completion	8 February 2017
Estimated completion	2 March 2017
Sites	1 location across United States

Drugs / interventions tested

CB-0002B

Conditions studied

Erythema — all drugs for Erythema →
Sensitisation — all drugs for Sensitisation →

Sponsor

CAGE Bio Inc. — full company profile →

Who can join

Adults 21 to 67, any sex, with Erythema or Sensitisation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Consumer products or raw materials designed for consistent reapplication to areas of the skin may, under proper conditions, prove to be contact sensitizers or irritants in certain individuals. It is the intention of a Repeat Insult Patch Test (RIPT) to provide a basis for evaluation of this irritation/sensitization potential if such exists.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Long-Lasting Skin Protectant Based on CG-101, a Deep Eutectic Solvent Comprising Choline and Geranic Acid.
Shevachman M, Mandal A, Gelston K, Mitragotri S, et al · · 2022 · cited 7× · PMID 36381128 · DOI 10.1002/gch2.202200064

Verify or expand the search:

Other recruiting trials for Erythema

Currently open trials in the same condition.

NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT02876107 — Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer · Phase 2 · active not recruiting
NCT02411656 — Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative B · Phase 2 · active not recruiting

Other CAGE Bio Inc. trials

Trials by the same sponsor.

NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting
NCT06923228 — A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis · Phase 2 · completed
NCT06810050 — Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Derma · Phase 2 · completed
NCT05487963 — Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis · Phase 1, PHASE2 · completed
NCT05202366 — An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04498676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CAGE Bio Inc.
Last refreshed: 4 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04498676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing